The efficacy of paroxetin, a selective serotonin reuptake inhibitor (SSRI), in AD-related depression has been shown to depend on the BDNF G196A gene polymorphisms, since A allele carriers display better therapeutic response [88]. Here, BDNF is linked to depressive symptom measurement.